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T cell lymphoma (TCL) is a heterogenous group of lymphoid malignancies representing
about 30–40% of all canine lymphomas and often harboring a very aggressive behavior.
WHO classification identifies the majority of TCLs as peripheral TCL, but other subtypes
with peculiar presentation and outcome have been recognized. This review aims to
explore the use of flow cytometry for refining the diagnosis of canine TCL, putting a
particular emphasis on the identification of some peculiar immunotypes, such as T zone
lymphoma; on the investigation of putative prognostic markers; and on the evaluation of
lymphoma stage and of the minimal residual disease.
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INTRODUCTION
T cell lymphoma (TCL) is a heterogeneous group of lymphoid neoplasms stemming from T cells.
It represents about 30–40% of canine lymphomas. Prevalence of B vs. TCLs varies among different
breeds with TCL being highly prevalent in Irish Wolfhound, Shih Tzu, Airedale Terrier, Cavalier
King Charles Spaniel, Yorkshire Terrier, Siberian Husky, and some other breeds (1).
Solid presentation with enlarged lymph nodes or the increased volume of any other lymphoid
organ are distinctive traits; these features easily allow a distinction between lymphoma and
leukemia, such as T chronic lymphocytic leukemia, which, on the contrary, originates from
bone marrow or spleen. Despite highly variable cytological aspects, most TCLs fall under the
umbrella of peripheral T cell lymphoma (PTCL), not otherwise specified (NOS), according to
WHO classification (2). T-zone lymphoma (TZL) and T lymphoblastic lymphoma (LL) are
two other commonly found TCL morphotypes, whereas enteropathy-associated TCL, cutaneous
epitheliotropic TCL, mediastinal lymphoma, and hepatocytotropic/hepatosplenic lymphoma
constitute uncommon findings. The updated Kiel classification identifies several different
cytological subtypes of TCL, thus confirming their extremely heterogeneous morphology (3)
(Table 1). According to this scheme, TCL could be further divided into low-grade TCLs,
characterized by indolent behavior, and high-grade TCLs, characterized by a very aggressive course
with median survival time statistically lower than its B cell counterpart (4).
IDENTIFICATION OF T CELL LINEAGE
Several antibodies have been generated to recognize specific canine lymphoid markers and to
define normal T cell subpopulations via flow cytometry (FC). Antibodies against surface epitopes
are highly preferable for FC. Antibodies capable of recognizing intracellular epitopes represent
another option, but they do require one or more additional permeabilization steps that may alter
cell morphology. This said, in the absence of any definitive reactivity to membrane antigens,
intracellular labeling for cytoplasmic CD3 can be performed to confirm a T cell origin. Antibodies
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TABLE 1 | Possible correlation between updated Kiel classification and WHO
classification for TCLs according to Ponce et al. (3).
Updated Kiel classification WHO classification
PRECURSOR T CELL LYMPHOMA
Lymphoblastic lymphoma Precursor T cell lymphoblastic
lymphoma/leukemia
MATURE T CELL LYMPHOMA
Low-grade Prolymphocytic T cell chronic lymphocytic
leukemia/prolymphocytic leukemia
Pleomorphic small cells Peripheral T cell Lymphoma,
unspecified
Small clear cell/T zone
lymphoma
Peripheral T cell Lymphoma,
unspecified
High-grade Pleomorphic mixed Peripheral T cell Lymphoma,
unspecified
Pleomorphic large cell Peripheral T cell Lymphoma,
unspecified
Immunoblastic Peripheral T cell Lymphoma,
unspecified
Plasmocytoid Peripheral T cell Lymphoma,
unspecified
Aggressive large granular Enteropathy-type T cell lymphoma
OR natural killer leukemia OR
extranodal nasal-type
CUTANEOUS LYMPHOMA
Cutaneous T cell, low-grade Mycosis fungoides/Sezary syndrome
Cutaneous T cell,
high-grade
Cutaneous T cell lymphoma
prelabeled with different fluorochromes are recommended to
identify co-expressions and to reduce the number of cells
needed for a complete antibody panel. Common antibodies used
to phenotype T cell markers and expected reactivity in non-
neoplastic cells are reported in Table 2.
T-helper cells are the most frequent lymphocyte subset in
canine lymph nodes (5) and can be easily recognized for their
positivity to CD4, CD3, CD5, andMHC II and for their prevalent
positivity to TCRαβ and, if activated, to CD25. A peculiar
subset of CD4+ T-regulatory cells (T-regs), representing <1%
of lymphocytes in circulating blood and <5% in lymph nodes,
can be identified for their high expression of CD25 and for the
co-expression of nuclear antigen Fox-P3 (6).
T-cytotoxic cells are less frequent in lymph nodes, spleen, and
peripheral blood and may be easily identified for positivity to
CD8, CD3, CD5, and MHC II.
In the thymus, besides mature T-helper and T-cytotoxic cells,
a mixed population of immature T cells co-expressing CD4
and CD8 (double-positive thymocytes) or lacking both antigen
expression (double-negative T cells) are found.
Less frequently, T cells may express CD11d and/or TCRγδ.
These phenotypes are often suggestive of splenic or, less
frequently, intestinal origin (7). These cells, in some instances,
can feature a large granular lymphocyte (LGL) morphology (8).
TABLE 2 | Common antibodies used for the characterization of T cells in dog and
expected reactivities.
Target Antibody clones Reactivity
CD3 CA17.2A12 T cells
CD3cy CD3-12 T cells
CD5 YKIX322.3 T cells and a subset of B cells
CD4 YKIX302.9 T-helper cells
CA13.1E4
CD8α YCATE55.9 T-cytotoxic cells
CA9.JG3
CD8β CA15.4G2 T-cytotoxic cells
CD45 YKIX716.13 All leukocytes
CA12.10C12
CD44 IM7 All hematopoietic cells
CD18 CA1.4E9 All leukocytes
MHC II YKIX334.2 Monocytes, Histiocytes, Lymphocytes
CA2.1C12
TCR αβ CA15.8G7 Most T cells
TCRγδ CA20.6A3 Gamma-delta T cell subset
CA20.8H1
CD25 P4A10 Activated lymphocytes
ACT-1
CD11d CA11.8H2 Splenic T cells and histiocytes
FoxP3 FJK-16s Activated cells, T-Reg cells
Ki67 MIB-1 Proliferating cells
DIFFERENTIATING REACTIVE AND
NEOPLASTIC T CELLS
When it comes to differentiating between reactive and neoplastic
T cell populations, distinguishing paracortical hyperplasia from
TZL represents the most challenging step (9). Paracortical
hyperplasia is an infrequent transitory hyperplastic condition due
to chronic dermatitis or to some specific antigens stimulating
T response (such as in Leishmaniosis or in viral infections).
It generally represents the immune response first phase, and
it precedes plasma cell proliferation (10). Differentiation via
cytology may be inconclusive, and FC should be considered the
most rapid and effective way to differentiate. This is due to the
very peculiar phenotype of TZL (CD45-CD5+CD21+) that can
be easily detected using a multicolor approach (11, 12).
Differentiating between high-grade TCL and reactive lymph
node hyperplasia tends to be easier because hyperplastic lymph
nodes (with follicular and/or lympho-plasmacellular hyperplasia)
are generally composed of a mixed population of T and B
cells, sometimes with a slight increase of large B cells. The T
cell population is generally composed of a mixed population of
both CD4 positive and CD8 positive cells, suggesting polyclonal
expansion. On the contrary, most PTCL feature a homogeneous
expansion of a single T cell subpopulation. The presence of
medium to large T lymphoid cells with forward scatter (FSC)
higher than 1.3–1.5 times that of normal lymphocytes also
suggests lymphoma. Residual non-neoplastic B and T cells are
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generally few, and this supports the hypothesis of a clonal
expansion, confirming lymphoma.
Neoplasia also may be confirmed through the identification of
phenotypic aberrancies. Qualitative and quantitative aberrancies
are frequent, occurring in more than 75% of TCLs (13).
The most frequent phenotypic aberrancies are loss of CD5
or CD3 expression; loss or co-expression of both CD4 and
CD8; marked decrease/loss of MHC class II expression; loss of
CD45 or other pan-leukocyte antigen expression; and concurrent
expression of a B-specific antigen, such as CD21 or CD79. The
use of wide antibody panels increases the odds of detecting
aberrant phenotypes, which may be considered a hallmark of
neoplasia (13).
When mediastinal masses are composed of a lymphocyte-
rich population, FC of the lymphoid population is considered an
excellent tool to distinguish mediastinal lymphoma from non-
neoplastic normal lymphocytes, thus supporting thymoma. A
cutoff value of 10% of double positive CD4+CD8+ thymocytes
and small cell size (similar to that of a circulating lymphocyte) is
strongly supportive of thymoma (14).
DEFINING IMMUNOPHENOTYPE OF
CANINE LYMPHOMA
Immunophenotype is a widely accepted prognostic feature in
canine high-grade lymphoma (4, 15, 16). Immunohistochemistry
is the traditional tool performed to define immunophenotype,
but FC has recently gained popularity due to the availability
of wide antibody panels, its fast response and the possibility of
detecting co-expressions and of accurately quantifying antigen
expressions (17).
Consistent approaches and cutoff values to define TCLs,
however, are still lacking. Wilkerson et al. (18) considered
TCLs if 60% of the population expressed any T cell antigen.
A more recent study considered as inclusion criteria to define
TCL a lymph node with a cytology/histopathology suggestive of
lymphoma together with a positive reactivity to CD3, or CD4,
CD8, in more than 10% of large lymphoid cells (19). In another
study, more than 65% of large lymphoid cells or more than 80%
of total lymphoid cells being positive to CD4 were considered
essential to define CD4+ TCLs (20).
In a recent study on CD8+ and CD4–CD8– lymphomas,
TCL cases were identified by a discrete majority population of
T cells with a homogeneous phenotype or a population of T
cells showing at least one feature of aberrancy (21). In another
study from the same group, the T cell phenotype was defined
upon the expression of CD3 or CD5 with variable expression
of T cell subset antigens CD4 and CD8 (22); no cutoff values
were reported.
Considering the abovementioned papers, despite the lack
of a consensus, TCL is likely to be correctly diagnosed if
a lymph node presents with cytology/histology suggestive of
lymphoma and if (1) a prevalent population of medium-
to-large lymphoid cells (≥1.3 times the size of normal T-
lymphocytes) expresses uniformly CD3 and/or CD5; (2) more
than 80% of total lymphoid cells have a homogeneous expression
of CD4 or CD8; or (3) any aberrant phenotype in CD3 or
CD5 positive cells is present, including the loss of membrane
expression of CD3 in cells retaining cytoplasmic expression of
CD3 only.
In rare instances, co-expression of T and B lineage-specific
markers may occur. More specifically, CD21 may be expressed
in TZL, and CD79 may be aberrantly expressed in some PTCLs.
A comprehensive evaluation of a complete panel of anti-T
antibodies is normally enough to differentiate B cells from TCLs
with an aberrant expression of B cell markers, but in some cases,
some other ancillary tests (PARR and histopathology) might be
necessary although caution should be made using PARR as an
immunotyping method (23).
REFINING THE DIAGNOSIS OF TCL
SUBTYPES
Flow Cytometry is a valid and rapid tool not only to define T cell
lineage, but also to refine the classification of TCL subtypes in
addition to cytomorphology and histopathology.
Peripheral T Cell Lymphoma
Peripheral T cell lymphoma is the most widely distributed
TCL subtype and comprises a heterogeneous group of different
immunotypes with different cytological presentations and
variable outcomes. According to the updated Kiel classification
scheme adapted to the dog, PTCLs are characterized by six
morphological subtypes, namely pleomorphic small-cell,
small clear-cell, pleomorphic mixed, pleomorphic large-cell,
immunoblastic, and plasmacytoid lymphomas (3). Among
PTCLs, the most frequent phenotype is CD45+CD3+
CD4+MHC II–/low (Figure 1) (19, 20). In all PTCL
subtypes, CD5 expression is usually positive, but a loss of
CD5 and CD3 may aberrantly occur and have a possible
prognostic meaning. CD25 is generally negative, suggesting
that they are inactive cells. TCRαβ is highly prevalent. This
immunophenotype occurs in 43–45% of multicentric TCLs
according to two different studies (19, 22). Forward scatter
properties show a medium-to-large size with median FSC 1.4
times greater than in non-neoplastic lymphocytes (22). This
subtype exhibits a consistent gene expression profile with the
positive regulation of phosphatidylinositol 3-kinase (PI3K)
activity. Phosphatidylinositol 3-kinase works together with AKT
and mTOR to regulate the cell cycle, leading to increased cell
proliferation and survival. The AKT/PI3K/mTOR signaling
axis is usually antagonized by the product of phosphatase and
tensin homolog gene (PTEN), a tumor suppressor gene that is
downregulated in CD4+ TCL as well (22).
The less frequent immunophenotypes of PTCL are
CD45+CD3+CD8+MHC II– and CD45+CD3+CD8–
CD4–MHCII– comprising about 11.9 and 13.5% of TCLs,
respectively (19).
A recent study based on 119 cases demonstrated that
the former immunophenotype is often associated with a
cutaneous localization, whereas the latter more frequently affects
mediastinal lymph nodes (21). Forward scatter properties are
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FIGURE 1 | Flow cytometric presentation of a PTCL. (A) Forward scatter (FSC) vs. side scatter (SSC) plot after doublet exclusion showing a unique population of
medium-to-large sized cells. (B,C) CD5 vs. CD21 plot (B) and CD3 vs. CD4 plot (C) of P2-gated cells showing a predominant population of CD5+CD3+CD4+ cells.
similar between the two subtypes, with median values of FSC
>1.2 times in neoplastic cells than in normal lymphocytes.
Other possible immunotypes are rare, but may
include CD3+CD4+CD8+, CD3+CD4+MHC II+, and
CD3+CD8+MHCII+ (19). However, specific studies on these
immunotypes including histopathology and the evaluation of
CD45 expression to exclude TZL are still lacking.
Lymphoblastic Lymphoma
Lymphoblastic lymphoma is a rare subtype identified in about
10% of TCL cases and about 3% of all canine lymphoma
(3). According to the WHO classification, LL is considered a
solid variant of T cell acute LL and is generally classified as a
neoplasm arising from precursor cells. Despite the homogeneous
population of small cells without an evident nucleolus, LL is
an aggressive high-grade lymphoma, and the mitotic index is
often very high. The outcome is generally poor without any
statistical difference compared with CD4+ PTCL. One study
(24) described a high prevalence of LL in the boxer breed,
harboring a less aggressive course and a longer survival. A
recent study on CD4+ TCL reported an overlapping of gene
expression profiles between PTCL and LL in dogs (22). In terms
of FC, the prevalent immunophenotype of LL is similar to
that of PTCL (CD45+CD3+CD4+MHC II–), and despite the
supposed origin from precursor cells, CD34 is generally negative.
Terminal deoxynucleotidyl transferase (TdT), which is often used
to confirm lymphoblastic nature in human LL (25), has not yet
been optimized for dogs.
In cases characterized by small-sized cells and no expression of
precursor markers, the FC determination of proliferative activity
can be useful to grade the tumor. A significant difference between
low- and high-grade lymphomas, according to the updated Kiel
classification, has been shown both for Ki67 expression (26)
and S-phase fraction (27), and a cutoff of 12.2 and 3.15% was
proposed, respectively, independent of the lineage. Nevertheless,
in the study by Poggi et al. (26), T cell high-grade lymphomas
presented higher Ki67 values compared with B cell high-grade
forms (45.0 vs. 29.3%).
T-Zone Lymphoma
T-zone lymphoma is a low-grade indolent lymphoma occurring
in about 10% of TCL. Cytologically TZL can be described
as a lymphocytic, small clear-cell lymphoma. Neoplastic cells
are easily recognized using a multicolor approach for their
characteristic loss of CD45 and for the frequent aberrant
expression of CD21, a B cell antigen, in the context of a
CD3+CD5+MHC II+ lymphoma (11, 12) (Figure 2). Although
rare, loss of CD45 expression may also occur in other lymphoma
subtypes besides TZL (28). CD25 is frequently expressed in
TZL, thus confirming the neoplastic cell activation status.
Expression of CD4 and CD8 may be variable (CD4+CD8–,
CD4–CD8+, CD4–CD8–, or CD4+CD8+) without any evident
correlation with outcome. Due to the very peculiar phenotype,
TZL also may be easy to recognize in its earlier phases, when a
mixed population of residual non-neoplastic lymphocytes is still
present, in cases of concurrent lymphomas in the same node (29–
31) or, again, when they are detected in non-lymphoid tissues,
such as peripheral blood and bone marrow, which are infiltrated
in more than 90% of cases (32). The low proliferative activity
reported by TZLs is described in two studies focusing on B and
TCLs and supports the low aggressiveness of the tumor (26, 27).
Several studies confirm the indolent behavior of this subtype,
making aggressive chemotherapy unnecessary in most dogs with
TZL (4, 11, 32, 33).
Studies on FC aspects in dogs with other TCL subtypes are
fragmentary and based on very limited caseloads. Limited data
are due to the frequent extranodal localizations that impair
the overall quality of FC samples. According to a study, in
fact, <60% of extranodal lymphoma were suitable for FC
processing, compared with more than 90% of nodal ones (34).
Immunohistochemistry and other techniques are more suitable
to investigate this kind of lesions.
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FIGURE 2 | Flow cytometric presentation of a TZL. (A) Forward scatter (FSC) vs. side scatter (SSC) plot after doublet exclusion showing a prevalent population of
medium sized cells. (B,C) FSC vs. CD45 plot (B) and CD5 vs. CD21 plot (C) of P2-gated cells showing that medium-sized cells are CD45–CD5+CD21+dim.
Hepatosplenic/Hepatocytotropic
Lymphomas
Keller et al. (35) described a series of nine cases of
hepatosplenic/hepatocytotropic lymphomas. Immunophenotype
was assessed via FC, and immunohistochemistry and neoplastic
cells expressed CD3+ (5/7), TCRαβ- (5/5), TCRγδ+ (3/5),
CD11d+ (6/7). CD8α was inconsistently expressed in 4/6 cases,
and CD4 and CD8β were not expressed in any of the cases.
The positivity to CD11d suggests an origin from the splenic
red pulp and may help to differentiate hepatosplenic from
hepatocytotropic lymphomas; these findings are consistent with
what has been described in human medicine (36).
Cutaneous Epitheliotropic T Cell
Lymphoma
Cutaneous Epitheliotropic T Cell Lymphoma (CETL) is
commonly investigated via immunohistochemistry because
cutaneous lesions are difficult to sample for FC and the
presence of non-neoplastic reactive lymphocytes may affect
FC interpretation. Flow cytometry may be useful to evaluate
immunophenotype in infiltrated lymph nodes from primary
CETL or in peripheral blood if Sezary syndrome is present (37).
In these cases, neoplastic cells are CD3+CD8+TCRγδ+ and
frequently lack CD5 expression (38).
Mediastinal Lymphoma
Flow cytometric features from seven cases of mediastinal
lymphoma were reported in a small case series (14). Four out
of seven cases expressed CD4; one expressed only CD45, CD34,
and CD14 and exhibited T cell clonality by PARR analysis, and
one was of B cell origin. The last case was double positive
for CD4+CD8+ but was mainly composed of large cells. The
authors concluded that FC is a useful tool for discriminating
mediastinal masses and that thymoma could be ruled out
in all cases in which <10% of the small lymphocytes were
CD4+CD8+. However, a more recent paper (39) describes
expansion of CD4–CD8– cells in a case of canine thymoma,
partially contradicting the previously published paper.
Enteropathy-Associated T Cell Lymphoma
Enteropathy-associated T Cell Lymphoma (EATL) is generally
investigated via immunohistochemistry and shows positivity to
CD3 and occasionally to CD30, a marker of anaplastic lymphoma
in humans (40). In rare instances, aberrant co-expression of B cell
antigen CD20 is possible (41). To the best of our knowledge, no
FC studies in EATL are available in dogs.
REFINING THE PROGNOSIS OF T CELL
LYMPHOMA
Outcomes of TCLs vary from poorly aggressive TZL with an
indolent course (the majority of cases) to highly aggressive PTCL
and hepatosplenic lymphoma. Being that TCLs comprise a wide
spectrum of different entities, each of them featuring a different
biological behavior and outcome, an accurate definition of the
immunophenotype is crucial for predicting outcome and setting
up a tailored therapy. Even though specific studies on prognosis
in TCLs are fragmentary, different subtypes could likely have
different prognostic factors.
Flow Cytometry is likely to be the best available tool to
accurately detect TZL given the very peculiar immunophenotype
and the loss of CD45 expression. The presence of CD45–CD5+
cells in lymph nodes and, in most cases, in peripheral blood
allows the suspicion of TZL also in its earlier stages, despite the
lack of a marked lymphoadenomegaly in palpable lymph nodes.
To date, no specific immunophenotypic prognostic markers for
TZL have been described, but median survival time is reported
to range between 637 and 930 days according to different
studies (11, 12, 42). However, some aggressive cases featuring a
similar immunophenotype but leading to short survival time are
sometimes described (28, 43).
Peripheral T cell lymphomas are generally associated with
short survival times [162 days according to (15)]. A recent
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study defined shorter survival times and progression-free
intervals (PFI) if CD4+MHC II– phenotype is found (160 and
108 days, respectively) (19). Unfortunately, CD45 expression
was not included in this study, and the inclusion of some
TZLs (expressing high MHC II) in the caseload may have
contributed to bias in the comparison. In another study (22), no
differences were found in survival times among CD4+MHCII–,
CD8+MHCII–, and CD4–CD8–MHCII–, but large cell size was
associated with a significantly shorter PFI and overall survival
(20, 22). CD5 expression (20) or loss of CD3 expression or co-
expression of CD79a (44) were also moderately associated with
shorter survival time in CD4+MHC II– PTCLs.
Considering all these findings, FC immunophenotyping seems
to be useful to better refine the subtype of TCL and to differentiate
PTCL from TZL. Furthermore, large size and aberrant loss of
CD3, or aberrant expression of CD79 may be linked to a more
aggressive course.
In addition to defining the degree of malignancy, Ki67 values
have proven useful for stratifying high-grade B cell lymphomas
with different prognosis (45). Different levels of Ki67 expression
were also described within high-grade TCLs (26). However,
whether it can represent a prognostic index for TCLs has yet to
be determined.
STAGING T CELL LYMPHOMA
Flow cytometry is an effective tool for defining infiltration
of neoplastic cells in different tissues, mainly in liquid ones
such as peripheral blood (PB) and bone marrow (BM). The
impact of the stage on the prognosis of canine lymphoma is
not consistent among different studies, and the current findings
are often influenced by the inclusion of different lymphoma
subtypes. Also, the strategy to detect infiltration (microscopic
evaluation, immunohistochemistry, FC, PARR) and the cutoff
values used vary among studies, thus strongly affecting results.
Some studies, however, suggest that stages, in particular, stage V
(i.e., infiltration of PB and/or BM or any other extra lymphoid
tissue)may affect outcomes differently in different subtypes.Most
studies on this issue have been focused on B cell lymphomas
(46, 47), and no specific studies on the prognostic significance
of PB and BM infiltration are available when it comes to TCLs.
As described, PTCLs are a very heterogeneous group in
terms of immunophenotype and morphology, suggesting that
the strategies used to detect neoplastic infiltration in peripheral
and medullary blood may differ. Multicolor FC may help to
easily detect the percentage of CD3+CD4+MHC II– neoplastic
cells in PB and BM and to distinguish this circulating
neoplastic cells from residual non-neoplastic T-helper cells
(MHC II+). Similarly, CD3+CD8+MHC II–, CD3+CD4–CD8–
, or CD3+CD4+CD8+ lymphomasmay be accurately quantified
using a multicolor approach. Other strategies may be used if
aberrant patterns are expressed, such as loss of CD3 or CD5
expression. In these cases, double labeling for CD3 and CD5
may easily identify neoplastic cells. In contrast, differentiation
between neoplastic and residual circulating lymphocytes can
be challenging if the immunophenotype of neoplastic cells is
similar to that of normal T-helper (CD4+MHC II+) or T-
cytotoxic (CD8+MHC II+) lymphocytes and no aberrancies
are present. In these instances, a larger cell size compared
with that of circulating lymphocytes can help to suspect
neoplastic infiltration.
To the best of our knowledge, no specific studies (featuring a
consistent caseload of PTCLs) on the prognostic significance of
PB or BM infiltrations are available, but some findings suggest
that the presence of leukemic cells is related to a bad outcome in
TCL (19), thus suggesting a possible prognostic role. This said,
cutoff values to define leukemic infiltration were not specified.
T-zone lymphoma is associated with the presence of neoplastic
circulating cells in more than 90% of cases (32) with or
without lymphocytosis. BM is often mildly or not infiltrated, and
cytopenia is generally scarce. Neoplastic circulating cells are easy
to detect usingmulticolor FC and double labeling for CD45/CD5.
Sometimes their detection in PBmay precede the development of
an evident solidmass. Despite the frequent peripheral infiltration,
the prognosis of TZL is generally quite good, and no data support
a prognostic role of PB or BM infiltration to date.
EVALUATION OF MINIMAL RESIDUAL
DISEASE
From a technical standpoint, the same strategies used to stage
TCLs can be used to evaluate the effects of chemotherapy and to
monitor the minimal residual disease (MRD). Minimal residual
disease via FC has been suggested as a possible feasible method
to monitor the effect of chemotherapy and to predict relapse in
canine diffuse large B cell lymphoma (48). At present, however,
no specific studies on the evaluation of MRD via FC and its
possible prognostic role in canine TCL are available.
FUTURE PERSPECTIVES
Although the availability of specific antibodies for most T cell
subpopulations improved the diagnosis of TCL, there is still
a lack of specific antibodies for some peculiar subtypes, such
as natural killer cells, precursor T cells, and/or antibodies that
may potentially be useful to better understand the prognosis
and peculiar risk factors. Again, the commercial availability of
antibodies labeled with more different fluorochromes would
improve the multicolor approach, allowing detection also of a
rare population of cells.
Also, the clinical significance of staging PB and BM infiltration
of TCLs is far from being completely understood, and multi-
institutional prospective studies with a standardized approach
and therapy are needed to obtain adequate statistic power.
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